Lancashire and South Cumbria
Formulary
Formulary
5 Infections
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
This chapter of the formulary is under development, please use local/national antimicrobial guidelines to support prescribing choices.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
The formulary development team can be contacted here: mlcsu.lscformulary@nhs.net
Prescribers must follow the relevant local and national guidance when treating an infection. Some anti-infectives require approval from the local Trust microbiology team for use, consult local guidance for further information.Not all anti-infectives listed in this chapter will be available in all localities; availability will be guided by local need and resistance patterns. |
05-01-05 Macrolides
| Clarithromycin |
|
Formulary
|
Intravenous infusion 500mg |
 LSCMMG: Critical Care Intravenous Drug Monographs |
|
| Erythromycin |
|
Formulary
|
Tablets e/c 250mg |
 MHRA: Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban MHRA: Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis |
|
Links
- Blackpool Teaching Hospitals: Antimicrobial Formulary
- British Association for Sexual Health and HIV
- Central Lancashire/LSCFT/Morecambe Bay Primary Care: NICE Summary of antimicrobial prescribing guidance - managing common infections
- East Lancashire Primary Care: Antimicrobial guide primary care
- East Lancashire Secondary Care: Antimicrobial guide secondary care
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (App store)
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (Google)
- LSCMMG: Critical Care Intravenous Drug Monographs
- LSCMMG: Critical Care Intravenous Drug Monographs
- MHRA Drug Safety Update Dec 2020: Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban
- MHRA Drug Safety Update Dec 2020: Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban
- MHRA Drug Safety Update Dec 2020:Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis
- MHRA Drug Safety Update Dec 2020:Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis
- MHRA: Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban
- MHRA: Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban
- MHRA: Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis
- MHRA: Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis
- MHRA: Hydroxychloroquine, chloroquine: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions
- NICE CG165: Hepatitis B (chronic): diagnosis and management
- NICE Evidence summary (ESUOM13) :Gastroparesis in adults: oral erythromycin
- NICE Evidence summary (ESUOM13): Gastroparesis in adults: oral erythromycin
- NICE evidence summary (ESUOM37): Cystic fibrosis: long-term azithromycin
- NICE evidence summary (ESUOM38) : Non-cystic fibrosis bronchiectasis: long-term azithromycin
- NICE NG110: Prostatitis (acute): antimicrobial prescribing
- NICE NG111: Pyelonephritis (acute): antimicrobial prescribing
- NICE NG114: Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing
- NICE NG117: Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing
- NICE NG120: Cough (acute): antimicrobial prescribing
- NICE NG125: Surgical site infections: prevention and treatment
- NICE NG138: Pneumonia (community-acquired): antimicrobial prescribing
- NICE NG139: Pneumonia (hospital-acquired): antimicrobial prescribing
- NICE NG141: Cellulitis and erysipelas: antimicrobial prescribing
- NICE NG152: Leg ulcer infection: antimicrobial prescribing
- NICE NG153: Impetigo: antimicrobial prescribing
- NICE NG182: Insect bites and stings: antimicrobial prescribing
- NICE NG184: Human and animal bites: antimicrobial prescribing
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG190: Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG198: Acne vulgaris: management
- NICE NG199: Clostridioides difficile infection: antimicrobial prescribing
- NICE NG240: Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management
- NICE NG50: Cirrhosis in over 16s: assessment and management
- NICE NG51: Sepsis: recognition, diagnosis and early management
- NICE NG78: Cystic fibrosis: diagnosis and management
- NICE NG79: Sinusitis (acute): antimicrobial prescribing
- NICE NG84: Sore throat (acute): antimicrobial prescribing
- NICE NG91: Otitis media (acute): antimicrobial prescribing
- NICE NG95: Lyme disease
- UKMI Q &A: Erythromycin and Statin Interaction
- UKMI Q &A: Erythromycin and Statin Interaction
- University Hospitals of Morecambe Bay: Antimicrobial guide secondary care
- West Lancashire Primary Care: Pan Mersey antimicrobial guide
- WHO: AWaRe classification of antibiotics for evaluation and monitoring of use, 2023